Pageloader -->

Govt Gives Emergency Use Approval to 2 Covid Vaccines, 1 Antiviral Drug

28 DEC 2021

Govt Gives Emergency Use Approval to 2 Covid Vaccines, 1 Antiviral Drug

 

The approval comes a day after the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorisation for the above two vaccines and one anti-viral drug.

The Centre has given an emergency use authorisation approval to two vaccines and one antiviral drug to strengthen its fight against the ongoing Covid-19 pandemic, Union health minister Mansukh Mandaviya said on Tuesday.

“Further strengthening the fight against Covid-19, CDSCO, health ministry has given 3 approvals in a single day for CORBEVAX vaccine, COVOVAX vaccine, anti-viral drug Molnupiravir for restricted use in an emergency situation,” Mansukh Mandaviya posted on Twitter.

The approval comes a day after the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorisation for the above two vaccines and one anti-viral drug.

Covovax will be made by the Serum Institute of India (SII) while Biological-E will make the Corbevax vaccine.

Health minister Mandaviya said on Tuesday that Corbevax is the country's first indigenously developed RBD protein sub-unit vaccine against Covid-19.

The number of vaccines that have received emergency use authorisation has now increased to eight.

Till now, Covishield, Covaxin, Sputnik V, Moderna, Johnson and Johnson and ZyCoV-D have so far received the authorisation.

Molnupiravir, Merck's Covid-19 pill will be manufactured by 13 companies in India to treat adult patients and who have a high risk of progression of the disease.

“Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situations for treatment of adult patients with Covid-19 and who have a high risk of progression of the disease,” Mandaviya also tweeted on Tuesday.

People familiar with developments told news agency PTI that Molnupiravir is not authorised for use in patients less than 18 years of age and for initiation of treatment in patients requiring immediate hospitalisation due to the coronavirus at that stage.

The drug is also not authorised for use for longer than five consecutive days and pre-exposure or post-exposure prophylaxis for prevention of Covid-19 for pregnant women.

 

According to the Union health ministry, India has administered 1.43 billion Covid-19 vaccine doses so far and more than 839 million of all adults have received at least one dose.

India will begin vaccinating those aged 15-18 from January 3 and start administering Covid-19 booster shots as a precautionary measure to healthcare and frontline workers from January 10.

Published on Dec 28, 2021 11:42 AM IST

Written by Harshit Sabarwal | Edited by Meenakshi Ray, New Delhi

 

Comments (0)


Today
8:03am
Hi Jenna! I made a new design, and i wanted to show it to you.
8:03am
It's quite clean and it's inspired from Bulkit.
8:12am
Oh really??! I want to see that.
8:13am
FYI it was done in less than a day.
8:17am
Great to hear it. Just send me the PSD files so i can have a look at it.
8:18am
And if you have a prototype, you can also send me the link to it.

Monday
4:55pm
Hey Jenna, what's up?
4:56pm
Iam coming to LA tomorrow. Interested in having lunch?
5:21pm
Hey mate, it's been a while. Sure I would love to.
5:27pm
Ok. Let's say i pick you up at 12:30 at work, works?
5:43pm
Yup, that works great.
5:44pm
And yeah, don't forget to bring some of my favourite cheese cake.
5:27pm
No worries

Today
2:01pm
Hello Jenna, did you read my proposal?
2:01pm
Didn't hear from you since i sent it.
2:02pm
Hello Milly, Iam really sorry, Iam so busy recently, but i had the time to read it.
2:04pm
And what did you think about it?
2:05pm
Actually it's quite good, there might be some small changes but overall it's great.
2:07pm
I think that i can give it to my boss at this stage.
2:09pm
Crossing fingers then

Details